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Abstract
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Regulators of G protein signaling are proteins that accelerate the termination of effector
stimulation after G protein-coupled receptor activation. Many regulators of G protein signaling
proteins are highly expressed in the brain and therefore considered potential drug discovery targets
for central nervous system pathologies; for example, here we show that RGS12 is highly expressed
in microdissected mouse ventral striatum. Given a role for the ventral striatum in psychostimulantinduced locomotor activity, we tested whether Rgs12 genetic ablation affected behavioral
responses to amphetamine and cocaine. RGS12 loss significantly decreased hyperlocomotion to
lower doses of both amphetamine and cocaine; however, other outcomes of administration
(sensitization and conditioned place preference) were unaffected, suggesting that RGS12 does not
function in support of the rewarding properties of these psychostimulants. To test whether
observed response changes upon RGS12 loss were caused by changes to dopamine transporter
expression and/or function, we prepared crude membranes from the brains of wild-type and
RGS12-null mice and measured dopamine transporter-selective [3H]WIN 35428 binding,
revealing an increase in dopamine transporter levels in the ventral–but not dorsal–striatum of
RGS12-null mice. To address dopamine transporter function, we prepared striatal synaptosomes
and measured [3H]dopamine uptake. Consistent with increased [3H]WIN 35428 binding,
dopamine transporter-specific [3H]dopamine uptake in RGS12-null ventral striatal synaptosomes
was found to be increased. Decreased amphetamine-induced locomotor activity and increased
[3H]WIN 35428 binding were recapitulated with an independent RGS12-null mouse strain. Thus,
we propose that RGS12 regulates dopamine transporter expression and function in the ventral
striatum, affecting amphetamine- and cocaine-induced increases in dopamine levels that
specifically elicit acute hyperlocomotor responses.
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Psychostimulant drugs of abuse such as (+)-amphetamine (AMPH) and cocaine are among
the most widely abused substances in the USA (Center for Behavioral Health Statistics and
Quality, 2015). These psychostimulants impose severe liabilities of high abuse potential,
capacity to induce psychoses, considerable neurotoxicity, and mortality (Ciccarone, 2011;
Heal et al., 2013). The locomotor-activating and rewarding properties of these
psychostimulants are dependent on the mesolimbic dopamine (DA) system of the brain
(Adinoff, 2004; Kauer and Malenka, 2007; Nutt et al., 2015; Thomas et al., 2008), defined
as the projections from DAergic cell bodies in the ventral tegmental area (VTA) to
presynaptic terminals in the nucleus accumbens (NAc) of the ventral striatum (vSTR).
Dopaminergic signaling within the vSTR is central to psychostimulant-induced locomotor
activity (Ikemoto, 2002): lesioning of DAergic terminals within the NAc–but not in the
dorsal striatum (dSTR)–by local injection of 6-hydroxydopamine markedly reduces the
hyperlocomotor responses to the dopaminergic indirect agonists AMPH and cocaine (Kelly
and Iversen, 1976). Similarly, microinjections of AMPH or cocaine into the NAc–but not
dSTR–increase locomotion and rearing behavior in rodents (Carr and White, 1987; Delfs et
al., 1990; Kelley et al., 1989; Staton and Solomon, 1984).
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AMPH and cocaine exert their effects by increasing extracellular DA levels in the vSTR via
their action at the dopamine transporter (DAT; refs. (Federici et al., 2014; Giros et al.,
1996)), which acts to translocate released DA back into the presynaptic DA terminal, thus
terminating neurotransmission at post-synaptic DA receptors. However, the mechanisms by
which AMPH and cocaine modulate DAT are mechanistically distinct. AMPH acts as an
indirect dopaminergic agonist in two ways: first, the drug acts as a substrate for (and hence,
a competitive inhibitor of) DAT (Sitte and Freissmuth, 2010), whose role is to re-uptake
dopamine after its release (Gainetdinov, 2008). Upon entry into dopaminergic terminals,
AMPH also acts as a substrate for the vesicular monoamine transporter, whose role is to
transport synaptoplasmic dopamine into vesicles for release (Sulzer, 2011). Once inside
dopaminergic vesicles, AMPH causes release, through reverse transport of the vesicular
monoamine transporter, of free dopamine into the synaptoplasm (Sitte and Freissmuth,
2010). In addition, AMPH causes release of that free DA through DAT, thereby increasing
synaptic levels of dopamine (Sitte and Freissmuth, 2010). Cocaine acts more simply: it is not
a DAT substrate, rather, it is a competitive inhibitor of the protein (Rothman, 1990). Cocaine
blocks the ability of DAT to re-uptake released dopamine, thereby increasing levels of
dopamine in the synapse (Nestler, 2005). Thus, each drug (AMPH and cocaine) ultimately
yields increased levels of synaptic dopamine in dopaminergic (DAT-expressing) synapses.
These increased levels of dopamine in response to AMPH or cocaine act on post-synaptic,
dopamine-responsive, G protein-coupled receptors (GPCRs) to elicit responses postsynaptically (Schultz, 2002).
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DAT expression, subcellular trafficking, and DA uptake function are all tightly regulated by
a host of protein interactants (Torres, 2006), such as receptors, kinases, and scaffolds. In
particular, several groups have identified presynaptic GPCRs and scaffolding proteins that
directly and/or functionally interact with DAT (Torres, 2006), suggesting that GPCRdependent, multiprotein networks are critical to DAT function. RGS12, a member of the
‘regulators of G protein signaling’ (RGS) protein superfamily (Snow et al., 1997, 1998), has
not previously been associated with DAT regulation. RGS proteins are known to accelerate
the inactivation of GPCR-activated Gα subunits (i.e. guanine nucleotide triphosphate-bound
(GTP-bound) Gα subunits) by stimulating their intrinsic GTPase activity (Berman et al.,
1996). This inactivation is followed by the reassociation of GDP-bound (i.e. inactive) Gα
subunits with Gβγ subunits, thereby terminating signaling originally evoked by free GTPbound Gα subunits (e.g. inhibition of adenylyl cyclase; (Clark and Traynor, 2004)) and/or
free Gβγ subunits (e.g. stimulation of G protein-coupled inwardly rectifying potassium
(GIRK) channels; (Zhou et al., 2012)).
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As many RGS proteins are expressed in the central nervous system (CNS; e.g. ref. Gold et
al., 1997), they are suspected to play key roles in neuronal function and behavior (Neubig
and Siderovski, 2002). For example, RGS14, the closest related paralog to RGS12, is
integral to hippocampal synaptic plasticity underlying learning and memory (Lee et al.,
2010). Several RGS proteins, including RGS12 and RGS14, are endowed with functional
domains other than the RGS domain (Kimple et al., 2011). In addition to being a Gαdirected GTPase-accelerating protein (GAP) (Snow et al., 1998), RGS12 contains four
additional functional motifs: a post-synaptic density (PSD95)/drosophila disc large tumor
spressor/zona occludens-1 binding protein (PDZ) binding domain (common among
scaffolding proteins), a phosphotyrosine binding domain, tandem Ras binding domains, and
a GoLoco motif (which sequesters GDP-bound Gα subunits) (Kimple et al., 2002; Snow et
al., 1998; Willard et al., 2007). Thus, the function of RGS12 in vivo need not be restricted to
Gα-directed GAP activity in opposition to GPCR activation; for example, we have shown
that RGS12 acts as a scaffold for Ras, Raf, and mitogen-activated protein kinase kinase
(MEK) in prolonging nerve growth factor (NGF)-stimulated extracellular signaling related
kinase (ERK) signaling and stimulating axonogenesis by dorsal root ganglion neurons, as
detailed elsewhere (Willard et al., 2007). To explore more deeply the potential roles for
RGS12 function in the CNS, we created both conventional and conditional mouse knockout
strains and conducted subsequent behavioral (locomotion, sensitization, conditioned place
preference) and biochemical (tissue radioligand binding, synaptosome uptake and release)
studies. Based on our findings, we propose that RGS12 modulates the expression and
function of DAT in the vSTR, thus explaining decreased hyperlocomotor responses in
RGS12-null mice to AMPH or cocaine compared with wild-type littermates.
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Methods
Animals
The generation of two independent strains of RGS12-null mice (constitutive Rgs12Δ5–8/Δ5–8
and Cre-dependent Rgs12Δ5–6/Δ5–6) is described in Figure 1 and Supplementary Material,
Figure S1. Both mouse strains are in the C57BL/6J background. Mice were housed under
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standard temperature, humidity, and lighting conditions (12 h light/12 h dark). All
behavioral experiments performed during the light cycle using mice between 8–10 weeks of
age. All mice were provided food and water ad libitum. All experiments were conducted in
accordance with West Virginia University Animal Care and Use Committee and followed
the National Institute of Health guidelines for use of animals in research. The procedures of
the behavioral assays are described below and were conducted according to previously
published methods (as cited); mice were used for only one behavioral assay involving either
acute or chronic drug dosing (i.e. all drug-based studies were performed with drug-naïve
mice; there is no sequence of multiple, drug-based experimental trials to define for
individual mice used in this study).
In situ hybridization

Author Manuscript

In situ hybridization with an antisense riboprobe directed against Rgs12 was performed in
order to assess the distribution of Rgs12 mRNA in brain. cDNA from the mouse Rgs12 open
reading frame (full-length) was subcloned into a pBluescript II SK vector by restriction
enzyme digestion. In vitro transcription with T7 RNA polymerase was conducted to produce
a digoxigenin-labeled antisense riboprobe. In situ hybridization was then performed by the
University of North Carolina Neuroscience Center In Situ Hybridization Core using
standardized protocols (UNC-Chapel Hill).
Immunoblots
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Immunoblot analyses of microdissected dopaminergic brain regions (frontal cortex, dorsal
and ventral striatum, and midbrain) were performed in order to identify which regions
contained RGS12 protein, to compare the relative abundances of RGS12 protein across
selected regions, and to verify complete knockout of RGS12 protein in Rgs12Δ5–8/Δ5–8 mice.
Mice were injected with a lethal dose of pentobarbital (200 mg/kg, intraperitoneal (ip)),
decapitated, rapidly dissected, and frozen on dry ice. dSTR, vSTR, and midbrain were
sonicated in 10 volumes of radioimmunoprecipiation assay buffer containing 25 mM TrisHCl (pH 7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS) (Pierce) supplemented with protease inhibitors (Halt protease inhibitor
cocktail, Thermo Fisher Scientific, Waltham, Massachusetts, USA). Lysates were cleaned by
centrifugation at 20,800×g for 20 min and pellets were discarded. Proteins were then
separated by SDS-polyacrylamide gel electrophoresis on a gradient 4–15% gel (BioRad),
electro-transferred to nitrocellulose membranes, and incubated overnight (4°C) with a
monoclonal primary antibody directed against the N-terminus of RGS12 (generated inhouse) or beta-actin (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Blots were
then probed with horseradish peroxidase-conjugated goat anti-mouse secondary antibodies
and visualized by chemiluminescence (Pierce). Data were derived from a sample size of
n=6–9 per genotype per experiment.
Locomotor assays
AMPH- or cocaine-induced locomotor activity assessments were carried out in order to
evaluate behavioral phenotypes in RGS12-null mice. Open field locomotor activity was
evaluated in a 16×16 photobeam activity system (PAS) under standard environmental
conditions (San Diego Instruments, San Diego, California, USA). Horizontal locomotor
J Psychopharmacol. Author manuscript; available in PMC 2019 February 01.
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activity was measured as the sum of the total x and y coordinate beam breaks collected every
five minutes. Acute psychostimulant-induced locomotor activity experiments were carried
out over three days. On Day 1, mice were habituated to locomotor chambers over 150
minutes to reduce the influence of novelty. On Day 2, all mice we allowed to habituate to
locomotor chambers for 30 min before ip administration of saline (0.9% NaCl) at a volume
10 mL/kg and locomotor activity was measured over 110 min.
On Day 3, mice were habituated to locomotor chambers for 30 min and then injected with dAMPH (1, 3, or 5 mg/kg, ip) (Chen et al., 2007; Salahpour et al., 2008;) or cocaine (10, 20,
or 40 mg/kg, ip) (Jung et al., 2013; Ramsey et al., 2008) dissolved in saline (ip, at a final
volume of 10 mL/kg). Psychostimulant-induced hyperlocomotion was then measured over
110 min. All drugs were obtained from Sigma-Aldrich (St Louis, Missouri, USA). Data
were derived from a sample size of n=7–23 per genotype per experiment.

Author Manuscript

Psychostimulant-induced locomotor sensitization
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Sensitization experiments were performed in order to assess whether RGS12-null mice
exhibited reduced responsiveness to repeated administration of AMPH or cocaine as was
observed with acute hyperlocomotion induced by these psychostimulants. Experiments were
performed as previously described (Steinkellner et al., 2014) with minor modifications.
Briefly, mice were habituated to locomotor chambers on Days 1 and 2 as described in acute
psychostimulant-induced locomotor activity experiments. Mice were then administered dAMPH (2 mg/kg, ip) or cocaine (20 mg/kg, ip) (Ramsey et al., 2008) for six consecutive
days (d1–d6) to induce sensitization under the conditions described for Day 3 of acute
psychostimulant-induced locomotor activity experiments. After the sixth day of
psychostimulant administration, the drug was withdrawn for 14 days. Following washout
(d20), mice were challenged with d-AMPH (2 mg/kg, ip) or cocaine (20 mg/kg, ip) and
horizontal locomotor activity was evaluated. Data were analyzed by two-way, repeated
measures analysis of variance (ANOVA). Data were derived from a sample size of n=6–9
per genotype per experiment.
Conditioned place preference (CPP)

Author Manuscript

CPP was conducted with RGS12-null mice in order to evaluate whether RGS12 influences
the rewarding properties of AMPH or cocaine. CPP studies were performed in a twochambered apparatus (Med Associates Inc., ENV-3013-2, Latham, NY USA) with the
paradigm described by Ramsey and colleagues (Ramsey et al., 2008) with minor
modifications. The two chambers of the CPP apparatus contained distinguishable floor
grating (grid floor vs rod floor) and colored walls (white vs black). Each experiment
consisted of habituation, preconditioning, conditioning, and post-conditioning phases.
Habituation (Day 1) was carried out to reduce the influence of apparatus novelty. Mice were
allowed free access to either chamber for 30 min and measurements of time spent in each
chamber was measured. For the preconditioning phase (Day 2), mice were again allowed
free access to either chamber for 30 min and time spent in each chamber was measured to
determine the least-preferred chamber of each mouse. Preference on Days 1 and 2 were
comparable (data not shown). The next day (Day 3) began the conditioning phase. Mice
were injected with either d-AMPH (2 mg/kg, ip) or cocaine (20 mg/kg, ip) and were
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restricted to the least preferred chamber for 30 min. On Day 4, mice were injected with
saline (0.9% NaCl, ip) and restricted to the other chamber for 30 min. The remainder of the
conditioning phase consisted of two more repetitions of alternating drug (Days 5 and 7) and
saline (Days 6 and 8). For the postconditioning test phase, CPP was determined by allowing
mice free access to either chamber and measuring the time spent for 30 min. No differences
in chamber preference were identified between habituation (Day 1) and preconditioning day
(Day 2). Preconditioning and postconditioning were calculated by subtracting the time spent
(s) in the preferred chamber (as determined on Day 2) from the least preferred chamber (as
determined on Day 2). Data were analyzed by two-way, repeated measures ANOVA. Data
were derived from a sample size of n=7–8 per genotype per experiment.
Preparation of brain sections and immunohistochemistry for c-Fos
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Psychostimulant-induced c-Fos immunohistochemistry was performed in order to determine
whether RGS12-null mice showed a reduction in neural activity specifically within the NAc
of the vSTR. Mice received ip injection of saline or d-AMPH (3 mg/kg). Following 90 min,
mice were anesthetized with pentobarbital (200 mg/kg) and transcardially perfused with 4%
paraformaldehyde. Perfused brains were post-fixed overnight and then placed in 30%
sucrose solution until brains sank. Cryoprotected brains were then frozen overnight at −80°C
and 40-μm free-floating sections were prepared. Sections were incubated with a polyclonal
anti-c-Fos primary antibody (1:100; Santa Cruz, Dallas, Texas, USA) overnight at 4°C,
followed by incubation of a flurophore-conjugated goat anti-rabbit secondary antibody
(Thermo Fisher Scientific, Waltham, MA, USA) for two hours at RT. Psychostimulantinduced c-Fos expression was visualized on an Evos epifluorescent microscope and c-Fospositive nuclei were counted in a 0.16-mm2 field of the dSTR and vSTR. Anatomical
landmarks, such as the anterior commissure, corpus callosum, and septum, were utilized to
demarcate the dSTR and vSTR. Three independent sections separated by 200 μm were
counted per mouse, and presented data were determined by computing the average number
of c-Fos-positive nuclei per field in 3–4 mice per genotype.
Preparation of synaptosomes and measurement of [3H]dopamine uptake and release

Author Manuscript

These biochemical experiments were performed to assess whether the observed reductions
in acute psychostimulant-induced hyperlocomotion were correlated with changes in DA
uptake and/or AMPH-induced DA release. For [3H]dopamine uptake experiments, dorsal
and ventral striatal synaptosomes were prepared by homogenizing brain tissue from 3–4
mice per genotype in 10 volumes ice-cold sucrose buffer (10% sucrose, 5 mM HEPES, pH
7.4) with a Potter-Elvehjem homogenizer (10 strokes). Homogenates were then centrifuged
at 1000×g for 10 min and supernatants containing crude synaptosomes were maintained on
ice. Synaptosomes were then added to tubes containing Krebs-Ringer uptake buffer (120
mM NaCl, 20 mM Tris-HCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl, 10 mM glucose, 1
mM ascorbic acid, and 0.1 mM pargyline) plus [3H]dopamine (33.5 μCi, Perkin-Elmer,
Bridgeville, Pennsylvania, USA) and incubated for 10 min at room temperature (RT) for
uptake to occur. Non-specific [3H]dopamine uptake was determined in the presence of 10
μM cocaine and subtracted from total uptake. Uptake was terminated by rapid filtration
(Brandel harvester) through 0.1% polyethelyneimine-soaked Whatman GF/B filters with icecold Krebs-Ringer buffer and washed three times before radioactivity measurement via
J Psychopharmacol. Author manuscript; available in PMC 2019 February 01.
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liquid scintillation counting. Data were analyzed with nonlinear fitting software (GraphPad
Prism 7) to determine Vmax and Km. AMPH-induced [3H]dopamine release assays were
performed as previously described (Rothman et al., 2001) with minor modifications. Briefly,
dorsal and ventral striatal synaptosomes were prepared as described above but with ice-cold
sucrose buffer supplemented with 1 μM reserpine. Synaptosomes were then incubated to
steady-state with 5 nM [3H] dopamine (30 min) in Krebs-Ringer buffer supplemented with 1
μM reserpine. Following incubation, 900 μL of preloaded synaptosomes were added to
12×75 mm polystyrene tubes containing d-AMPH (1×10–8.5–1×10–5 M) in Krebs-Ringer
buffer. The release reaction proceeded for five minutes, then was terminated by rapid
filtration over Whatman GF/B filters with ice-cold Krebs-Ringer buffer, washed three times,
and radioactivity was measured via liquid scintillation counting. Data were analyzed with
nonlinear fitting software (GraphPad Prism 7) to determine EC50. Data were derived from a
sample size of n=6–12 per genotype per experiment.
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Preparation of brain tissue and measurement of [3H]WIN 35428 binding
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DAT saturation binding experiments were conducted in order to determine whether the
increased DA uptake in RGS12-null mice was associated with elevated DAT protein levels.
Dorsal and ventral striatal brain regions were rapidly dissected and frozen on dry ice. Tissue
was then homogenized with a Polytron homogenizer with 10 volumes of transporter binding
buffer (50 mM Tris-HCl, 120 mM NaCl, and 5 mM MgCl, pH 7.4). Homogenates were then
centrifuged at 20,800×g for 20 min. The resulting pellet was then resuspended in transporter
binding buffer and added to tubes containing [3H]WIN 35428 (1.75 to 52.5 nM) and
incubated for one hour at RT. Nonspecific binding was determined in the presence of 10
GBR12909. Binding was terminated by rapid filtration over Whatman GF/B filters with icecold transporter binding buffer, washed three times, and radioactivity was measured via
liquid scintillation counting. Data were analyzed with nonlinear fitting software (GraphPad
Prism 7) to determine Bmax and Kd. Data were derived from a sample size of n=6–9 per
genotype per experiment.
High-performance liquid chromatography (HPLC) with dual-cell electrochemical detection
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HPLC on microdissected dopaminergic brain regions was carried out to assess whether
tissular DA levels differed between RGS12-null and wild-type mice. Dorsal and ventral
striatal brain regions were rapidly dissected and frozen on dry ice. Tissue was then sonicated
in 10 volumes of 0.3 N perchloric acid and homogenates were centrifuged at 12,000×g for
15 min. Supernatants were collected, passed through a 0.22 μm filter, and dopamine levels in
the homogenates were determined by HPLC with dual-cell electrochemical detection.
Cleared lysates underwent automated direct injection of 10 μL into a Dionex Ultimate 3000
HPLC system equipped with a pump (ISO-3100BM, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) linked to an autosampler (WPS-3000TBRS, Thermo Fisher Scientific,
Waltham, MA, USA), ESA HPLC column (MD-150×3.2) and dual coulometric/
amperometric electrochemical detectors (ECD-3000RS, Thermo Fisher Scientific, Waltham,
Massachusetts, USA) set at −170 mV and +400 mV, respectively. Mobile phase (MD-TM;
Thermo Fisher Scientific, Waltham, Massachusetts, USA) was pumped at a flow rate of 0.6
mL/min. Chromatograms were analyzed using Chromeleon software and dopamine peak
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height (concentration) was determined from a standard curve. The identity of the DA peak in
the sample was confirmed by standard addition.
Statistics
All data are presented as means±standard error of the mean (SEM). Statistical significance
was set at p<0.05 for all experiments, and data were analyzed by student’s t-test or two-way
ANOVA followed by Sidak’s post-hoc test where appropriate.

Results
RGS12 protein is abundantly expressed in the ventral striatum of the mouse CNS
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Our study was initiated by the generation of two independent strains of RGS12-null mice on
the C57BL/6J background (Figure 1(a)–(c)). Rgs12 mRNA was detected within the brain by
in situ hybridization in wild-type, but not in RGS12-null, mice (Figure 1(d), (e)). Rgs12 is
expressed in the VTA and the substantia nigra pars compacta (SNc) (Figure 1(d)); there was
also clear labeling of Rgs12 in the dentate gyrus and the cornu ammonis regions of the
hippocampus (HPC). As shown in Figure 1(e), there was also diffuse labeling of Rgs12 in
the striatum (STR) and cortex (CTX), as well as marked labeling of Rgs12 in the claustrum
(CLA). RGS12 protein immunoreactivity was detected in the midbrain (the seat of the VTA
and SNc) (Figure 1(f)); however, midbrain RGS12 protein content was low in comparison to
the high abundance of Rgs12 mRNA. There was also detectable RGS12 immunoreactivity in
the frontal CTX and dSTR (Figure 1(f)). RGS12 immunoreactivity was greater in the vSTR
than in frontal cortex, dSTR, or midbrain (Figure 1(g)). Quantification of immunoblots is
presented as the mean±SEM (n=6 per group), and statistical significance was assessed by
one-way ANOVA with Tukey’s multiple comparisons post-hoc analysis: e.g. frontal CTX vs
dSTR (p<0.05); dSTR vs vSTR (p<0.01); midbrain vs dSTR (not significant (ns)), p=0.72).
Despite dense RGS12 immunoreactivity, Rgs12 mRNA labeling in the vSTR is quite sparse
(Figure 1(e)).
RGS12 loss blunts hyperlocomotion to low doses of AMPH and cocaine

Author Manuscript

Given marked RGS12 expression in the vSTR, and an established role for the vSTR in
psychostimulant actions, as a next step we evaluated RGS12-null mice in psychostimulantinduced behavioral assays. Both RGS12-null mouse strains exhibited a markedly reduced
response to a standard hyperlocomotive-inducing dose (3 mg/kg) of AMPH compared with
wild-type littermates (Figure 2(a)–(c)). Data indicating lack of a saline effect (Figure 2(a))
are displayed as means±SEM (n=7–8 per group) and analyzed by two-way ANOVA:
genotype effect, F(1,13)=0.04, p=0.84; time, F(21,273)=5.4, p<0.0001; genotype×time,
F(21,273)=1.1, p=0.40. Data indicating reduced hyperlocomotion of conditional RGS12-null
mice to 3 mg/kg AMPH (Figure 2(b)) are displayed as means±SEM (n=7–8 per group) and
analyzed by two-way ANOVA: genotype effect, F(1,12)=8.9, p=0.011; time,
F(21,252)=11.3, p<0.0001; genotype×time, F(21,252)=3.2, p<0.0001. Data indicating
reduced hyperlocomotion of constitutive RGS12-null mice (Figure 2(c)) are means±SEM
(n=9–23 per group) and analyzed by two-way ANOVA: genotype effect, F(1,41)=18.6,
p<0.0001; time, F(21,861)=42.3, p<0.0001; genotype×time, F(21,861)=9.6, p<0.0001.
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An initial dose of 3 mg/kg AMPH was selected because it has been extensively
characterized as eliciting robust locomotor responses in wild-type C57BL/6 mice
(Medvedev et al., 2013; Ramsey et al., 2008; Salahpour et al., 2008). We next assessed
whether RGS12-null mice exhibit reduced locomotor responses to lower doses of AMPH.
We found that AMPH at 1 mg/kg was sufficient to observe hyperlocomotion in wild-type
mice relative to saline injection (Figure 2(d)); however, there was only a trend towards
reduced AMPH-stimulated hyperlocomotion in RGS12-null mice at this lower dose (Figure
2(d)). At a high dose of AMPH (5 mg/kg), the hyperlocomotive responses of wild-type and
Rgs12-null mice were identical (Figure 2(d)). Data from these additional AMPH doses are
displayed as means±SEM (n=8–23 per group) and analyzed by multiple t-test analysis:
saline, p=0.52; 1 mg/kg, p=0.057; 3 mg/kg, p<0.0001; 5 mg/kg: p=0.086.
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Having obtained the described results with AMPH, we proceeded to determine whether the
response to another dopaminergic psychostimulant, cocaine, was similarly affected upon
RGS12 loss. As shown in Figure 2(e), 10 mg/kg cocaine elicited a hyperlocomotive response
in wild-type mice that was markedly reduced in Rgs12-null mice. Data indicating reduced
hyperlocomotion to cocaine in RGS12-null mice are displayed as means±SEM (n=9–10 per
group) and analyzed by two-way ANOVA: genotype effect, F(1,17)=17.2, p=0.016; time,
F(21,357)=8.8, p<0.0001; genotype×time, F(21,357)=2.4, p=0.0006. In follow-up studies
with 20 mg/kg and 40 mg/kg of cocaine, doses established by others’ studies (Elliot, 2002;
Ramsey et al., 2008; Reith et al., 1991; Salahpour et al., 2008), we observed no genotypedependent differences in drug-induced hyperlocomotion (Figure 2(f)). Data from these
additional cocaine doses are displayed as means±SEM (n=7–20 per group) and analyzed by
multiple t-test analysis: saline, p=0.99; 10 mg/kg, p=0.02, p<0.01); 20 mg/kg, p=0.84; 40
mg/kg, p=0.72.

Author Manuscript

Both AMPH and cocaine are well known to exert their actions via the neurotransmitter DA
(Ciccarone, 2011). One possible explanation for these observations of reduced
hyperlocomotion is that, in RGS12-null mice, post-synaptic DA receptor sensitivity is
decreased. SKF 81927 is a selective D1-like (D1/D5) DA receptor full agonist (Desai et al.,
2005; Weed et al., 1993), which has been extensively characterized as eliciting robust
horizontal locomotor activity in mice (Desai et al., 2005; Medvedev et al., 2013; Scott et al.,
2005). However, we found no differences in hyperlocomotion between the two genotypes at
each of the three different doses of SKF 81927 tested (Figure 2(g)), suggesting a presynaptic, rather than a post-synaptic, effect of RGS12 loss on dopaminergic psychostimulant
action. Data on SKF 81927-mediated hyperlocomotion are displayed as means±SEM (n=8
per group) and analyzed by multiple t-test analysis: saline, p=0.73; 1 mg/kg, p=0.64; 3
mg/kg, p=0.59; 5 mg/kg, p=0.71.

Author Manuscript

RGS12 loss does not affect sensitization nor CPP
Having established a phenotype based on acute administration of AMPH or cocaine, we next
tested the effects of repeated dosings of these psychostimulants on RGS12-null mice with
doses known to elicit robust sensitization in wild-type C57BL/6 mice (Eisener-Dorman et
al., 2011; Ramsey et al., 2008). Despite recapitulating the reduced acute locomotor
responses to AMPH by RGS12-null mice (Figure 3(a)), sensitization to repeated
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administration of AMPH–a measure of neuronal plasticity of the mesolimbic dopamine
system (Berg and Olsson, 2004; Steketee and Kalivas, 2011)–was intact in RGS12-null mice
compared to wild-type littermates (Figure 3(b),(c)). Locomotion observations from the first
day of acute 2 mg/kg AMPH administration (Figure 3(a)) were analyzed by two-way
ANOVA: genotype effect, F(1,308)=10.3, p=0.002; time, F(21,308)=1.7, p=0.03;
genotype×time, F(21,308)=7.6, p=0.75. Locomotion observations from the sixth day of
acute 2 mg/kg AMPH administration (Figure 3(b)) were analyzed by two-way ANOVA:
genotype effect, F(1,14)=0.45, p=0.52; time, F(21,294)=36.2, p<0.0001; genotype×time,
F(21,294)=1.1, p=0.36. AMPH sensitization time-course data (Figure 3(c)) were analyzed
by two-way, repeated-measures ANOVA: genotype effect, F(1,14)=2.7, p=0.6; time,
F(6,84)=25.4, p<0.0001; genotype×time, F(6, 84)=25.4, p=0.95. Similarly, sensitization to
cocaine was not affected in RGS12-null mice (Figure 3(d)–(f)). Locomotion observations
from the first day of acute 20 mg/kg cocaine administration (Figure 3(d)) were analyzed by
two-way ANOVA: genotype effect, F(1,10)=0.31, p=0.59; time, F(21,210)=14.2, p<0.0001;
genotype×time, F(21,210)=3.6, p<0.0001. Locomotion observations from the sixth day of
acute 20 mg/kg cocaine administration (Figure 3(e)) were analyzed by two-way ANOVA:
genotype effect, F(1,10)=0.08, p=0.78; time, F(21,210)=17.7, p<0.0001; genotype×time,
F(21,210)=0.61, p=0.91. Cocaine sensitization time-course data (Figure 3(f)) were analyzed
by two-way, repeated-measures ANOVA: genotype effect, F(1,10)=1.0, p=0.33; time,
F(21,210)=17.4, p<0.0001; genotype×time, F(21,210)=0.73, p=0.80.
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In another behavioral paradigm elicited by repeated psychostimulant administration–CPP,
which measures the ‘rewarding’ properties of drugs (Tzschentke, 2007)–we observed no
differences in the effects of either AMPH or cocaine in RGS12-null vs wild-type mice
(Figure 3(g), (h)). CPP as induced by 2 mg/kg doses of AMPH was analyzed by two-way,
repeated-measures ANOVA: genotype effect, F(1,12)=0.23, p=0.64; time, F(1,12)=54.1,
p<0.0001; genotype×time, F(1,12)=0.04, p=0.84. CPP as induced by 10 mg/kg doses of
cocaine was analyzed by two-way, repeated-measures ANOVA: genotype effect,
F(1,14)=3.43, p=0.09; time, F(1,14)=41.4, p<0.0001; genotype×time, F(1,14)=0.04, p=0.84.
All CPP data are presented as means±SEM (n=6–9 per group).
AMPH-elicited neuronal excitation is reduced in the NAc upon RGS12 loss

Author Manuscript

In light of the locomotor data and RGS12 expression data, we suspected that RGS12 loss
might affect psychostimulant-dependent neuronal activation in at least one locus within the
vSTR: namely, the NAc. Therefore, we addressed this hypothesis by measuring c-Fos
induction in AMPH-treated RGS12-null and wild-type mice. c-Fos immunoreactivity
(measured as c-Fos-positive nuclei per field; Figure 4(a)) was pronounced in the NAc (i.e.
ventro-lateral to the anterior commissure (ac)) after an acute dose of 3 mg/kg AMPH.
Consistent with the reduced hyperlocomotion of RGS12-null mice to acute, low-dose
AMPH, c-Fos immunoreactivity was significantly reduced in the NAc of AMPH-treated
RGS12-null mice compared with wild-type littermates (Figure 4(b)). Conversely, in the
dSTR, the number of c-Fos-positive nuclei was not different between AMPH-treated
RGS12-null mice and wild-type littermates (Figure 4(b)). c-Fos immunoreactivity data are
presented as means±SEM (n=3–4 mice per group) and were analyzed by two-way ANOVA
with Sidak’s multiple comparisons: vSTR, p<0.0001; dSTR, p=0.85.
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The reduced effects of psychostimulants on RGS12-null mice could be explained by
increased DAT-mediated uptake in the vSTR of DA, the major neurotransmitter affected by
AMPH and cocaine (Ciccarone, 2011). Thus, to test this hypothesis, we next prepared
ventral and dorsal striatal synaptosomes from RGS12-null mice to measure [3H]dopamine
uptake. A significant increase in the Vmax (maximal rate of [3H]dopamine uptake) of
RGS12-null ventral striatal synaptosomes was observed as compared with wild-type ventral
striatal synaptosomes (Figure 5(a) and (b) inset); however, no genotype-specific differences
in Vmax were observed for dorsal striatal synaptosomes (Figure 5(b)). Km values were
equivalent between genotypes in both ventral and dorsal striatal synaptosomes (Figure 5(a)
and (b)). [3H]Dopamine uptake Vmax data are presented in Figure 5(b) as means±SEM
(n=9–12 per group) and were analyzed by genotype using two-way ANOVA with Sidak’s
multiple comparisons: vSTR, p=0.0054; dSTR, p=0.91 (ns). [3H]Dopamine uptake Km
values were as follows: vSTR, wild-type mice=0.36±0.16 μM, RGS12-null mice=0.33±0.16
μM; dSTR, wild-type mice mice=0.86±0.32 μM, RGS12-null mice=0.80±0.32 μM; two-way
ANOVA with Sidak’s multiple comparisons: vSTR, p=0.99; dSTR: p=0.49.
To evaluate whether the observed increase in [3H]dopamine uptake in the ventral striata of
RGS12-null mice was mediated specifically by DAT, we also performed [3H]dopamine
uptake studies using RGS12-null ventral striatal synaptosomes in the presence of the DATselective re-uptake inhibitor GBR12935 in order to quantify (and subtract out) non-specific
uptake. A significant increase in the Vmax of DAT-specific [3H]dopamine uptake was
observed in RGS12-null vSTR synaptosomes as compared with those derived from wildtype littermates (Figure 5(c)). DAT-specific [3H]dopamine uptake data are presented as
means±SEM (n=6 per group) and were analyzed by unpaired t-test: p=0.001.

Author Manuscript

DAT binding sites are significantly elevated in the ventral striatum

Author Manuscript

Data indicating increased DA uptake by ventral striatal synaptosomes prompted us next to
probe the expression levels of DAT in striatal tissue from RGS12-null mice. Radioligand
saturation binding assays were performed with [3H]WIN 35428 (a DAT-selective
radioligand) to determine the maximal number of DAT binding sites in wild-type and
Rgs12-null crude membrane fractions of ventral and dorsal striatal tissue. A marked increase
was seen in [3H]WIN 35428 binding to ventral striatal membrane fractions from Rgs12-null
mice compared with wild-type mice (Figure 5(d) and (e) inset). Although unable to
accurately determine Bmax given the absence of saturation binding, we were able to establish
relative expression levels of DAT by comparing the binding of wild-type and RGS12-null
ventral and dorsal striatal crude membrane fractions at the maximal concentration of
[3H]WIN 35428 tested (52.5 nM). As shown in the bar graph inset within Figure 5(e),
[3H]WIN 35428 binding to RGS12-null ventral striatal crude membrane fractions was
markedly greater than radioligand binding to wild-type ventral striatal crude membrane
fractions; however, there was no statistically significant, genotype-specific effect on
[3H]WIN 35428 binding to dorsal striatal crude membrane fractions. Data for [3H]WIN
35428 binding in Figure 5(e inset) are presented as means±SEM (n=6–9 per group) and
analyzed by genotype using two-way ANOVA with Sidak’s multiple comparisons: vSTR,
p=0.0051; dSTR, p=0.11 (ns).
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To assess whether the observed increase in vSTR DAT binding sites in Rgs12Δ5–8/Δ5–8 mice
was recapitulated in an independent mouse strain lacking RGS12 expression, we next
performed [3H]WIN 35428 binding assays on crude membrane fractions from Crerecombinase dependent RGS12-null (Rgs12Δ5–6/Δ5–6) mice (Figure 1(c) and Supplementary
Material, Figure S1(e); i.e. Rgs12fl/fl mice expressing an ubiquitously-expressed,
cytomegalovirus (CMV)-driven Cre transgene). We found that maximal DAT binding sites
are also elevated in this Rgs12Δ5–6/Δ5–6 mouse strain relative to wild-type (Rgs12+/+;
CMV::Cre) littermate controls (Figure 5(f)). Data for [3H]WIN 35428 binding in Figure 5(f)
are presented as means±SEM (n=6 per group) and were analyzed by genotype using
unpaired t-test: p<0.0001.

Discussion
Author Manuscript

Our major finding from these analyses is that the loss of RGS12 engenders reduced acute
responses (hyperlocomotion and c-Fos induction) in response to the psychoactive drugs
AMPH or cocaine. This reduction is likely caused by increased DA uptake in the vSTR–in
particular, the NAc–due to elevated levels of surface-exposed (and, hence, functional) DAT.
The presence of RGS12, in one (or more) brain region(s), must in some way negatively
regulate DAT expression levels and/or activity, given that RGS12 loss has been observed in
this study to increase DAT expression and activity, at least in the vSTR.

Author Manuscript

The expression pattern of Rgs12 mRNA compared with the distribution of RGS12 protein
renders it tempting to speculate that RGS12 is being synthesized in the dopaminergic
projections from the midbrain (i.e. the VTA and SNc; e.g. Figure 1(d)) and trafficked to
striatal terminals (e.g. Figure 1(f)) Put another way, RGS12 appears to be a pre-synaptic
protein in the STR. Furthermore, the lack of genotype-dependent differences in locomotor
responses to a post-synaptically active dopaminergic agonist (i.e. SKF 81927; Figure 2(g))
suggests RGS12 acts pre-synaptically. Biochemical data are also in line with this notion: the
expression and function of DAT, a pre-synaptic protein (Torres and Amara, 2007), are both
increased upon RGS12 loss (Figure 5). However, baseline DA levels in the vSTR and dSTR
of wild-type and RGS12-null mice are identical, as measured by HPLC with dual-cell
electrochemical detection (Supplementary Material, Figure S2). In addition, no changes
were observed in the levels of tyrosine hydroxylase, the rate-limiting enzyme for DA
synthesis (Daubner et al., 2011) (Supplementary Material, Figure S2). Thus, the observed
changes in DAT expression levels and function are likely a direct result of RGS12 loss, and
not necessarily caused indirectly by a compensatory upregulation (Jakowec et al., 2004;
Kimmel et al., 2001; Salvatore et al., 2016) in response to altered DA synthesis or basal
levels upon RGS12 loss per se.
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Despite reduced locomotor responses to acute administration of AMPH and cocaine,
RGS12-null mice developed locomotor sensitization and CPP to each drug in a manner
similar to wild-type mice. Although these latter behaviors are mediated by mesolimbic DA
(Baik, 2013; Henry et al., 1989; Steketee and Kalivas, 2011), their expression is found to be
dependent on neuroplastic changes (i.e. increased VTA excitability and firing rate) to postsynaptic NMDA glutamate and DA receptor signaling/expression levels, as well as to
somatodendritic DA autoreceptors located on VTA neurons (Henry et al., 1989;
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Neisewander et al., 1998; Ramsey et al., 2008; Tanabe et al., 2004; White and Wang, 1984).
These findings also support the notion that RGS12 is acting pre-synaptically and thus why
only acute behavioral responses to AMPH and cocaine are affected.
Biochemical assays revealed no significant differences in DAT levels or activity in the dSTR.
Thus, the phenomenon of RGS12 regulation of DAT appears to be region specific; i.e.
RGS12 affects DAT in the mesolimbic system (i.e. VTA to the NAc–a major effector of
locomotor behavior). Notably, the levels of RGS12 are greater in the ventral striatum than in
the dorsal striatum (Figure 1).

Author Manuscript

One possible explanation for this enrichment could be a functional and/or physical
interaction with pre-synaptic GPCR(s) in the vSTR that is not expressed or relevant in the
dSTR. For example, striatal DAT expression and function are potently regulated by two Gαicoupled GPCRs expressed on striatal presynaptic membranes: D2 receptors and κ-opioid
receptors (KORs). Activation of these receptors serves as a negative feedback mechanism
upon elevated striatal DA tone, thus augmenting DA uptake and increasing surface DAT
expression (Bolan et al., 2007; Kivell et al., 2014) in a region-specific manner. Acute
administration of KOR agonists increases DA uptake in vSTR, but not dSTR (Thompson et
al., 2000). Additionally, D2 receptor agonists decrease DAT expression in the dSTR, but
increase DAT expression in the vSTR (Kimmel et al., 2001). Thus, removal of RGS12 as a
negative regulator of G protein-mediated signaling downstream of either GPCR may feasibly
lead to augmented pre-synaptic D2 receptor and/or KOR-mediated signaling, resulting in
elevated DAT surface expression and DA uptake.
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There are several possible mechanisms by which RGS12 could impact DAT trafficking
and/or function, given the multiple protein-protein interaction domains present within
RGS12 (Kimple et al., 2002; Snow et al., 1998; Willard et al., 2007). One simple
explanation for involvement of RGS12 in curtailing DAT function evokes the C-terminal
GoLoco motif of RGS12– a guanine nucleotide dissociation inhibitor (GDI) activity that
results in the sequestration of inactive Gα subunits (Kimple et al., 2002), which normally reassociate with Gβγ subunits. This re-association blocks any signaling that is mediated by
Gβγ. Thus, by sequestering inactive Gα subunits, the GoLoco motif of RGS12 may extend
the lifetime of free Gβγ subunits, which are known to, among other things, inhibit DAT
activity (Garcia-Olivares et al., 2013).
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Another plausible explanation for RGS12 affecting DAT function in the vSTR lies in the
ability of RGS12 to interact with components of the mitogen activated protein kinase
MAPK/MEK/ERK cascade, the activity of which supports DAT trafficking to the cell
surface (Moron et al., 2003; Willard et al., 2007). We speculate that RGS12, as a
(MAPK)/MEK/ERK scaffold, diverts this signaling cascade from facilitating the trafficking
of DAT to the synaptic plasma membrane in the vSTR. Another possibility that cannot be
excluded is that RGS12, through its established interactions with Ras, Raf, MEK, and/or
other as-yet unidentified proteins, regulates transcription factors that negatively modulate the
transcription of DAT. To explore this possibility, we performed immunoblot analyses on
whole lysates of vSTR using a validated DAT antibody (Chen et al., 2006; Foster et al.,
2012; Garcia-Olivares et al., 2013; Steinkellner et al., 2012); total DAT levels were seen to
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be comparable in wild-type and RGS12-null ventral striatum (Supplementary Material,
Figure S2), arguing against any transcriptional effect (e.g. in VTA-to-NAc projection
neurons). Thus, we are currently assessing whether RGS12 regulates the trafficking of DAT
to the synaptic membrane in the vSTR.
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There is a clear dose-dependence to the differences seen in acute responses to AMPH and
cocaine between RGS12-null and wild-type mice (Figure 2). We suspect that this is due to a
saturation of DAT by the uptake inhibitors AMPH and cocaine at higher concentrations. We
propose that, at lower doses of DAT inhibitor (1 and 3 mg/kg AMPH; 10 mg/kg cocaine),
the excess DAT that is expressed in RGS12-null ventral striatum is available to clear more
synaptic DA, reducing the acute locomotor responses of RGS12-null mice vs those of wildtype mice. However, at higher doses of DAT inhibitor (5 mg/kg AMPH; 20 mg/kg and 40
mg/kg cocaine), even the extra DAT expressed in RGS12-null mice becomes saturated by
drug, so all DAT molecules in the vSTR of both genotypes are blocked, thereby eliminating
any difference in acute locomotor responses between RGS12-null and wild-type mice.
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This hypothesis of extra, unsaturated DAT in RGS12-null mice would suggest that DAT
levels would become saturated at lower doses in wild-type mice. Yet, in both genotypes,
locomotor response is seen to increase with 20 mg/kg cocaine over that of 10 mg/kg, and
again with 40 mg/kg cocaine over that of 20 mg/kg (Figure 2(f)). Therefore, an additional
possibility is that RGS12 loss affects the regulation of autoreceptors on DAT-positive
terminals, thereby lowering the threshold for pre-synaptic feedback by synaptic DA and
resulting in curtailed DA release at low drug concentrations. On the other hand, it has been
reported that 20 mg/kg cocaine increases locomotor response even in mice lacking vesicular
monoamine transporter 2 (VMAT2), critical for DA transport into synaptic vesicular stores
(Wang et al., 1997). Thus, another possibility to consider is a role for RGS12 in VMAT2
function affecting DA release–a role absent in RGS12-null mice but dependent on DAT
inhibitor dose for full elaboration and observation in behavioral outcomes.
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It is also notable that AMPH acts not only as an antagonist of DAT, but also as a releaser of
DA. This dual effect explains the increased locomotor activity elicited by AMPH compared
with cocaine, which is solely a DAT antagonist (Figure 2(d) vs 2(f), note the difference in yaxis scales). We propose that, at higher doses of AMPH (5 mg/kg), due to saturation of DAT,
the maximum quantity possible of DA is released (i.e. at 5 mg/kg, dopamine is completely
depleted from the pre-synaptic terminals of both wild-type and RGS12-null mice),
potentially explaining why there is no difference between the genotypes. Moreover, in
ventral striatal synaptosomal preparations, the ability of AMPH to enhance the release of
[3H]dopamine is not markedly different between wild-type and RGS12-null mice
(Supplementary Material, Figure S3). This latter observation suggest that RGS12 somehow
modulates the uptake functionality–but not the release functionality–of DAT. Molecular
studies to address this issue are currently underway.
In summary, our studies have uncovered a novel regulator of ventral striatal DAT expression
and activity: namely, RGS12. The neuroanatomical site(s) of RGS12 action and the
mechanism(s) by which it regulates ventral striatal DAT expression and function remain to
be identified. However, the observed functional interaction between RGS12 and DAT clearly
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impacts acute mesolimbic-dependent responses to dopaminergic psychostimulants. Future
work is required to establish the molecular determinants within both proteins that underlie
this regulation, be it direct (e.g. via possible RGS12/DAT interactions) or indirect via the
presynaptic regulation of G protein subunits or other intermediates.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Independent targeting of two separate ablations to the mouse Rgs12 locus. (a) Multiple,
protein-protein interaction domain architecture of the encoded regulators of G protein
signaling (RGS)12 protein, including a PSD-95/Dlg/ZO-1 (PDZ; orange) domain capable of
binding the C-termini of the mitogen-activated protein kinase (MAPK) middle-tier kinase
MAPK-kinase (MEK2) and the interleukin-8 receptor CXCR2 (Snow et al., 1998; Willard et
al., 2007), a phosphotyrosine-binding (PTB; pink) domain thought to bind the NGF receptor
TrkA (Willard et al., 2007), an RGS domain (yellow) which binds and inactivates
heterotrimeric G protein Ggdα subunits of the Gi/o subfamily (Snow et al., 1998), a tandem
repeat of Ras-binding domains (RBDs; cyan) that bind indicated members of the Ras
guanine nucleotide triphosphate (GTP) ase and MAPK first-tier (Raf) kinases (ref. Willard et
al., 2007), a GoLoco motif which binds inactive Gα subunits of the Gi subfamily (ref.
Kimple et al., 2002), and regions of predicted low complexity (rose). Vertical lines indicate
exon-exon junctions within the open-reading frame encoded by the Rgs12 mRNA. (b) and
(c) Mice lacking functional RGS12 (Rgs12Δ5-8/Δ5-8) were obtained from the Texas A and
M Institute of Genomic Medicine (TIGM) in a 129/Sv×C57BL/6 mixed background.
Because congenic C57BL/6 mice are standard for neuropsychopharmacological behavioral
assays, we back-crossed the TIGM Rgs12Δ5-8/Δ5-8 mice with C57BL/6J mice for more
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than ten generations. Henceforth, Rgs12Δ5-8/Δ5-8 mice will refer to congenic Rgs12Δ5-8/
Δ5-8 mice on the C57BL/6J background. Exons 5–8, encoding the entire polypeptide
sequence of the RGS domain of RGS12 (yellow; panel (a)), were targeted for replacement
with a neomycin resistance, drug-selectable marker. (d) Coronal in situ hybridization (Allen
Brain Atlas) reveals marked Rgs12 mRNA labeling in the ventral tegmental area (VTA) and
substantia nigra pars compacta (SNc), beds of the mesolimbic and nigrostriatal
dopaminergic soma. Analyses also reveal hippocampus (HPC) Rgs12 mRNA, particularly in
the dentate gyrus. (e) Coronal in situ hybridization from our group shows sparse Rgs12
mRNA in dorsal striatum (dSTR) and ventral striatum (vSTR) and cortex (CTX). Marked
labeling was observed in the claustrum (CLA). (f) Immunoblotting for RGS12 protein levels
in microdissected frontal cortex, dSTR, vSTR, and midbrain in wild-type (WT) and RGS12null mice. â-Actin immunoreactivity served as a loading control. (g) Densitometric analysis
demonstrates that RGS12 in vSTR is higher than frontal CTX, dSTR, and midbrain and,
specifically is 157% more abundant than in dSTR. Data are means±standard error of the
mean (SEM) (n=6 mice per group) relative to dSTR set to100%. One-way analysis of
variance (ANOVA) with Tukey’s multiple comparisons: dSTR vs frontal CTX p=0.018
(*p<0.05), dSTR vs vSTR p=0.0014 (**p<0.01), dSTR vs midbrain p=0.724 (not significant
(ns), p>0.05).
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Figure 2.
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Acute psychostimulant-induced locomotion in Rgs12-null mice. (a) Locomotor activity in
Rgs12 Δ5–6/Δ5–6 mice (i.e. conditional Rgs12fl/fl mice cross-bred with an ubiquitous
CMV::Cre transgene) following 30 min acclimation to activity chambers and then saline (at
a final volume of 10 mL/kg) administration. Data are means±standard error of the mean
(SEM) (n=7–8 per group). (b) (+)-amphetamine (AMPH) (3 mg/kg)-induced
hyperlocomotion in Rgs12 Δ5–6/Δ5–6 mice for 80 min following 30 min acclimation to
activity chambers. Data are means±SEM (n=7–8 per group). (c) AMPH (3 mg/kg)-induced
hyperlocomotion in constitutive Rgs12 Δ5–8/Δ5–8 mice for 80 min following 30 min
acclimation to activity chambers. Data are means±SEM (n=9–23 per group). (d) Cocaine (10
mg/kg)-induced hyperlocomotion in constitutive Rgs12 Δ5–8/Δ5–8 mice for 60 min
following 30 min acclimation to activity chambers. Data are means±SEM (n=9–10 per
group). (e) Total locomotion by constitutive Rgs12 Δ5–8/Δ5–8 mice over 80 min following
intraperitoneal (ip) injection of saline or various doses of AMPH after 30 min acclimation to
activity chambers. Data are means±SEM (n=8–23 per group). (f) Total locomotion by
constitutive Rgs12 Δ5–8/Δ5–8 mice over 60 min following ip injection of saline or various
doses of cocaine after 30 min acclimation to activity chambers. Data are means±SEM (n=7–
20 per group). (g) Total locomotion by constitutive Rgs12 Δ 5–8/Δ5–8 mice over 60 min
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following ip injection of saline or indicated doses of SKF 81927 after 30 min acclimation to
activity chambers. Data are means±SEM (n=8 per group).
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Figure 3.
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Psychostimulant-induced locomotor sensitization and conditioned place preference in
regulators of G protein signaling (RGS)12-null mice. Total locomotion over 80 min
following (+)-amphetamine (AMPH) (2 mg/kg; (a) and (b)) or 60 min following cocaine (20
mg/kg; (d) and (e)). Total locomotion normalized to Day 1 total locomotion plotted as fold
change across drug treatment days ((c) and (f)). Data are means±standard error of the mean
(SEM) (n=6–9 per group). Psychostimulant-induced conditioned place preference in Rgs12null mice. Data shown are the difference in the time spent between AMPH (2 mg/kg) (panel
(g))- or cocaine (10 mg/kg) (panel (h))-paired and saline-paired chamber for preconditioning (Day 2) and post-conditioning (Day 9). Data are means±SEM (n=7–8 per
group).
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(+)-Amphetamine (AMPH)-stimulated c-Fos induction in regulators of G protein signaling
(RGS)12-null mice. (a) Immunohistochemical analysis of c-Fos in the nucleus accumbens
(NAc) of RGS12-null and wild-type (WT) mice injected with AMPH (3 mg/kg). (b)
Quantification of the number of c-Fos-positive neurons per field in RGS12-null vs WT
dorsal striatum (dSTR) and ventral striatum (vSTR) (3–4 matched sections per genotype).
Data are means±standard error of the mean (SEM) (n=3–4 mice per group).
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Figure 5.
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Analysis of dopamine transporter (DAT) function and expression in regulators of G protein
signaling (RGS)12-null mice. [3H]Dopamine uptake in ventral (a) and dorsal (b) striatal
synaptosomes prepared from RGS12-null and wild-type mice. ((b, inset) Uptake rates
(Vmax) of [3H] dopamine in ventral and dorsal striatal synaptosomes derived from data in
panels (a) and (b); non-specific uptake determined in the presence of 10 μM cocaine. Data
are means±standard error of the mean (SEM) (n=9–12 per group). (c) Uptake rates (Vmax)
by DAT of [3H]dopamine in ventral striatal synaptosomes derived from data in
Supplementary Material, Figure S4; non-specific uptake determined in the presence of 10
μM GBR12935 (a selective dopamine reuptake inhibitor). Data are means±SEM (n=6 per
group). (d) and (e) Levels of DAT determined from [3H]WIN 35428 saturation binding
analysis of ventral (d) and dorsal (e) striatal crude membrane fractions. Non-specific binding
was determined in the presence of 10 μM GBR12935. ((e) inset) Maximal DAT binding sites
at 52.5 nM [3H]WIN 35428 in ventral and dorsal striatal membranes derived from data in (d)
and (e). Data are means±SEM (n=6–9 per group). (f) Maximal DAT binding sites at 52.5 nM
[3H]WIN 35428 in ventral striatal membranes derived from data in Supplementary Material,
Figure S4. Data are means±SEM (n=6 per group). dSTR: dorsal striatum; vSTR: ventral
striatum.
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